Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10

European Journal of Immunology

Volumn 39, Issue 8, 2009, Pages 2146-2160

  Bhaumik, Siddhartha Kumar ^a   Naskar, Kshudiram ^a   De, Tripti ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Cytokines; Immunoprophylaxis; Immunotherapy; Parasitic protozoan; Th1 Th2

Indexed keywords

ANTIMONY; ANTIMONY GLUCONATE; BETA N ACETYLGLUCOSAMINYLGLYCOPEPTIDE BETA 1,4 GALACTOSYLTRANSFERASE; COMPLETE SOLUBLE ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; PARASITE ANTIGEN; UNCLASSIFIED DRUG; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; IMMUNIZATION; LEISHMANIA DONOVANI; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RELAPSE; SKIN LEISHMANIASIS; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VACCINATION; VISCERAL LEISHMANIASIS; ANIMAL; BAGG ALBINO MOUSE; CLONAL ANERGY; GENE EXPRESSION; GENETICS; HAMSTER; IMMUNOLOGY; MACROPHAGE; MACROPHAGE ACTIVATION; METABOLISM; METHODOLOGY; PARASITIC LIVER DISEASE; PARASITOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; SYRIAN HAMSTER;

ANIMALS; ANTIGENS, PROTOZOAN; CLONAL ANERGY; CRICETINAE; CYTOKINES; DOWN-REGULATION; GENE EXPRESSION; IMMUNIZATION; INTERFERON-GAMMA; INTERLEUKIN-4; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIVER DISEASES, PARASITIC; MACROPHAGE ACTIVATION; MACROPHAGES; MESOCRICETUS; MICE; MICE, INBRED BALB C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN; T-LYMPHOCYTES; TH1 CELLS;

EID: 70249110436     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.200839017     Document Type: Article

References (63)

1. Modabber, F., Leishmaniasis. TDR 12th Programme Report 1995. pp. 135-146.
2. World Health Organization. Leishmaniasis Update, WHO 2007.
3. Murray, H. W., Berman, J. D., Davies, C. R. and Saravia, N. G., Advances in leishmaniasis. Lancet 2005. 366: 1561-1577.
4. Coler, R. N. and Reed, S. G., Second-generation vaccines against leishmaniasis. Trends Parasitol. 2005. 21: 244-249.
5. Bhaumik, S. K., Singh, M., Basu, R., Bhaumik, S., Roychoudhury, K., Naskar, K., Roy, S. and De, T., Virulence attenuation of a UDP-galactose/N- acetylglucosamine β1,4 galactosyltransferase expressing Leishmania donovani promastigote. Glycoconjugate J. 2008. 25: 459-472.
6. Dissanayake, S. and Shahin, A., Induction of interferon-gamma by Taenia crassiceps glycans and Lewis sugars in naive BALB/c spleen and peritoneal exudate cells. Mol. Immunol. 2007. 44: 1623-1630
7. Kropf, P., Freudenberg, M. A., Modelell, M., Price, H. P., Herath, S., Antoniazi, S., Galanos, C. et al., Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major. Infect. Immun. 2004. 72: 1920-1928.
8. Takeda, K., Kaisho, T. and Akira, S., Toll-like receptors. Annu. Rev. Immunol. 2003. 21: 335-376.
9. De, T. and Roy, S., Infectivity and attenuation of Leishmania donovani promastigotes: association of galactosyl transferase with loss of parasite virulence. J. Parasitol. 1999. 85: 54-59. (Pubitemid 29241882)
10. Engwerda, C. R. and Kaye, P. M., Organ-specific immune responses associated with infectious disease. Immunol. Today 2000. 21: 73-78. (Pubitemid 30069619)
11. Murray, H. W., Tissue granuloma structure-function in experimental visceral leishmaniasis. Int. J. Exp. Pathol. 2001. 82: 249-267.
12. Kaye, P. M., Svensson, M., Ato, M, Maroof, A., Polley, R., Stager, S., Zubairi, S. and Engwerda, C. R., The immunopathology of experimental visceral leishmaniasis. Immunol. Rev. 2004. 201: 239-253.
13. Chakrabarti, G., Basu, A., Manna, P. P., Mahato, S. B., Mandal, N. B. and Bandyopadhyay, S., Indolylquinoline derivatives are cytotoxic to Leishmania donovani promastigotes and amastigotes in vitro and are effective in treating murine visceral leishmaniasis. J. Antimicrob. Chemother. 1999. 43: 359-366.
14. Mullen, A. B., Baillie, A. J. and Carter, K. C., Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B. Antimicrob. Agents Chemother. 1998. 42: 2722-2725.
15. Croft, S. L., Sundar, S. and Fairlamb, A. H., Drug Resistance in Leishmaniasis. Clin. Microbiol. Rev. 2006. 19: 111-126.
16. Sundar, S. and Chatterjee, M., Visceral leishmaniasis - current therapeutic modalities. Indian J. Med. Res. 2006. 123: 345-352.
17. Murray, H. W. and Nathan, C. F., Macrophage microbicidal mechanisms in vivo: Reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J. Exp. Med. 1999. 189: 741-746.
18. Murray, H. W., Survival of intracellular pathogens within human mononuclear phagocytes. Semin. Hematol. 1988. 25: 101-111.
19. Mosser, D. M., Receptors on phagocytic cells involved in microbial recognition. Immunol. Ser. 1994. 60: 99-114.
20. Coffman, R. L., Lehman, D. A. and Rothman, P., Mechanism and regulation of immunoglobulin isotype switching. Adv. Immunol. 1999. 54: 229-270.
21. Pinelli, E., Rutten, V. P. M. G., Bruysters, M., Moore, P. F. and Ruitenberg, E. J., Compensation for decreased expression of B7 molecules on Leishmania infantum-infected canine macrophages results in restoration of parasite-specific T-cell proliferation and gamma interferon production. Infect Immun. 1999. 67: 237-243. (Pubitemid 29021654)
22. Murray, H. W., Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob. Agents Chemother. 2001. 45: 2185-2197.
23. Sundar, S., More, D. K., Singh, M. K., Singh, V. P., Sharma, S., Makharia, A., Kumar, P. C. and Murray, H. W., Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis. 2000. 31: 1104-1107.
24. Calvopina, M., Barroso, P. A., Marco, J. D., Korenaga, M., Cooper, P. J., Nonaka, S., and Hashiguchi, Y., Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis. Vaccine 2006. 24: 5645-5652. (Pubitemid 43867099)
25. Mukhopadhyay, S., Bhattacharyya, S., Majhi, R., De, T., Naskar, K., Majumdar, S. and Roy, S., Use of an attenuated leishmanial parasite as an immunoprophylactic and immunotherapeutic agent against murine visceral leishmaniasis. Clin. Diagn. Lab. Immunol. 2000. 7: 233-240.
26. Kaye, P. M., Curry, A. J. and Blackwell, J. M., Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J. Immunol. 1991. 146: 2763-2770.
27. Squires, K. E., Schreiber, R. D., McElrath, M. J., Rubin, B. Y., Anderson, S. L. and Murray, H. W., Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. J. Immunol. 1989. 143: 4244-4249.
28. Murray, H.W., Requirement for T cells and effects of lymphokines in successful chemotherapy for an extracellular infection. Experimental visceral leishmaniasis. J. Clin. Invest. 1989; 83: 1253-1257.
29. Alvar, J., Leishmania and human immunodeficiency virus co-infection: the first 10 years. Clin. Microbiol. Rev. 1997. 10: 298-319.
30. Cunningham, A. C., Parasitic adaptive mechanisms in infection by leishmania. Exp. Mol. Pathol. 2002. 72: 132-141.
31. Alexander, J. and Bryson, K., T helper (h)1/Th2 and Leishmania: paradox rather than paradigm. Immunol. Lett. 2005. 99: 17-23.
32. Murray, H. W., Lu, C. M., Mauze, S., Freeman, S., Moreira, A. L., Kaplan, G., and Coffman, R. L., Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 2002. 70: 6284-6293
33. Bhattacharyya, S., Ghosh, S., Jhonson, P. L., Bhattacharya, S. K. and Majumdar, S., Immunomodulatory role of interleukin-10 in visceral leishmaniasis: defective activation of protein kinase C-mediated signal transduction events. Infect. Immun. 2001. 69: 1499-1507.
34. Murray, H. W., Flanders, K. C., Donaldson, D. D., Sypek, J. P., Gotwals, P. J., Liu, J. and Ma, X., Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis. Infect. Immun. 2005. 73: 3903-3911.
35. Murray, H. W., Interleukin 10 receptor blockade - pentavalent antimony treatment in experimental visceral leishmaniasis. Acta Trop. 2005. 93: 295-301. (Pubitemid 40348833)
36. Murphy, M. L., Wille, U., Villegas, E. N., Hunter, C. A. and Farrell, J. P., IL-10 mediates susceptibility to Leishmania donovani infection. Eur. J. Immunol. 2001. 31: 2848-2856.
37. Karp, C. L., el-Safi, S. H., Wynn, T. A., Satti, M. M., Kordofani, A. M., Hashim, F. A., Hag-Ali, M. et al., In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J. Clin. Invest. 1993. 91: 1644-1648.
38. + regulatory T cells control Leishmania major persistence and immunity. Nature 2002. 420: 502-507.
39. Belkaid, Y., Hoffmann, K. F., Mendez, S., Kamhawi, S., Udey, M. C., Wynn, T. A. and Sacks, D. L., The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J. Exp. Med. 2001.194: 1497-1506.
40. Saha, S., Mondal, S., Ravindran, R., Bhowmick, S., Modak, D., Mallick, S., Rahman, M. et al., IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J. Immunol. 2007. 179: 5592-5603.
41. Reis e Sousa, C., Sher, A. and Kaye, P., The role of dendritic cells in induction and regulation of immunity to microbial infection. Curr. Opin. Immunol. 1999. 11: 392-399.
42. Chakraborty, D., Banerjee, S., Sen, S., Banerjee, K. K., Das, P. and Roy, S., Leishmania donovani Affects Antigen Presentation of Macrophage by Disrupting Lipid Rafts. J. Immunol. 2005. 175: 3214-3224. (Pubitemid 41170542)
43. Murray, H. W., Lu, C. M., Brooks, E. B., Fichtl, R. E., DeVecchio, J. L. and Heinzel, F. P., Modulation of T-Cell Costimulation as Immunotherapy or Immunochemotherapy in Experimental Visceral Leishmaniasis. Infect. Immun. 2003. 71: 6453-6462.
44. Jenkins, M. K., The role of cell division in the induction of clonal anergy. Immunol. Today 13: 69-73.
45. Saha, B., Das, G., Vohra, H., Ganguly, N. K. and Mishra, G., Macrophage-T cell interaction in experimental visceral leishmaniasis: failure to express costimulatory molecules on Leishmania-infected macrophages and its implication in the suppression of cell-mediated immunity. Eur. J. Immunol. 1995. 25: 2492-2498.
46. Corry, D. B., Reiner, S. L., Linsley, P. S. and Locksley, R. M., Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis. J. Immunol. 1994. 153: 4142-4148.
47. Brown, J. A., Greenwald, R. J., Scott, S., Schweitzer, A., Satoskar, A. R., Chung, C., Schopf, L. R. et al., T helper differentiation in resistant and susceptible and susceptible B7-deficient mice infected with Leishmania major. Eur. J. Immunol. 2002. 34: 1764-1772.
48. Elloso, M. M. and Scott, P., Expression and contribution of B7-1 (CD80) and B7-2 (CD86) in the early immune response to Leishmania major infection. J. Immunol. 1999. 162: 6708-6715. (Pubitemid 29309396)
49. Murphy, M. L., Engwerda, C. R., Gorak, P. M. and Kaye, P. M., B7-2 blockade enhances T cell responses to Leishmania donovani. J. Immunol. 1994. 159: 4460-4466.
50. Murray, H. W., Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intrac ellular adhesion molecule 1-dependent and -independent regulation. Infect. Immun. 2000. 68: 6294-6299.
51. Murray, H. W., Granulomatous inflammation: host antimicrobial defense in the tissue in visceral leishmaniasis, in: Gallin, J., Snyderman, R., Fearson, D., Haynes, B. and Nathan, C. (Eds.), Inflammation: Basic Principles and Clinical Correlates, 3rd Edn. Lippincott-Raven, Philadelphia, PA, pp. 977-994.
52. Baker, R. C. P. and Kaye, P. M., Leishmaniaisis, in: Zumla D. G. J. A (Ed.), The Granulomatous Disorder. Cambridge University Press, Cambridge, UK, pp. 212-234.
53. Sacks, D. and Noben-Trauth, N., The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2002. 2: 845-858.
54. Murray, H. W., Stern, J. J., Welte, K., Rubin, B. Y., Carriero, S. M. and Nathan, C. F., Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma. J. Immunol. 1987. 138: 2290-2297. (Pubitemid 17046286)
55. + cells in experimental visceral leishmaniasis. J. Immunol. 1988. 140: 3971-3977.
56. McElrath, M. J., Murray, H. W. and Cohn, Z. A., The dynamics of granuloma formation in experimental visceral leishmaniasis. J. Exp. Med. 1988. 167: 1927-1937.
57. Müller, I., Kropf, P., Etges, R. J. and Louis, J. A., Gamma interferon response in secondary Leishmania major infection: role of CD8+T cells. Infect. Immun. 1993. 61: 3730-3738.
58. + T cells requires the presence of cognate antigen. Infect. Immun. 2006. 74: 773-776.
59. Basu, R., Bhaumik, S., Basu, J. M., Naskar, K., De, T. and Roy, S., Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlateswith inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J. Immunol. 2005. 174: 7160-7171. (Pubitemid 40705683)
60. Carvalho, E. M., Barral, A., Pedral-Sampaio, D., Barral-Netto, M., Badaró, R., Rocha, H. and Johnson, W. D., Jr., Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J. Infect. Dis. 1992. 165: 535-540.
61. Stauber, L. A., Host resistance to Khartoum strain of Leishmania donovani. Rice Inst. Pamphlets 1958. 45: 80-83.
62. Roy, S., Scherer, M. T., Briner, T. J., Smith, J. A. and Gefter, M. L., Murine MHC polymorphism and T cell specificities. Science 1989. 244: 572-575. (Pubitemid 19140810)
63. Overbergh, L., Valckx, D., Waer, M., Mathieu, C., Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine 1999. 11: 305-312. (Pubitemid 29213178)